# Nutex Health Inc.: Form 10-Q for the period ended Sep 30, 2019

- Company: [Nutex Health Inc.](/companies/nutx.md) (CIK 1479681)
- Form: 10-Q
- Filed: 2019-11-19
- Accepted by EDGAR: Nov 19, 2019, 11:48 ET
- Period: 2019-09-30
- Accession: 0001607062-19-000457
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1479681/000160706219000457/igmb093019form10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1479681/000160706219000457/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2019-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2019-07-01 to 2019-09-30 | $7.5k | us-gaap:Revenues |
| Revenue | 9 months, 2019-01-01 to 2019-09-30 | $19.2k | us-gaap:Revenues |
| Cost of revenue | 3 months, 2019-07-01 to 2019-09-30 | $10.0k | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months, 2019-01-01 to 2019-09-30 | $26.3k | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2019-07-01 to 2019-09-30 | −$2.5k | us-gaap:GrossProfit |
| Gross profit | 9 months, 2019-01-01 to 2019-09-30 | −$7.2k | us-gaap:GrossProfit |
| Operating income | 3 months, 2019-07-01 to 2019-09-30 | −$363.8k | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2019-01-01 to 2019-09-30 | −$1.1m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2019-07-01 to 2019-09-30 | $10.0k | us-gaap:InterestExpense |
| Interest expense | 9 months, 2019-01-01 to 2019-09-30 | $234.3k | us-gaap:InterestExpense |
| Net income | 3 months, 2019-07-01 to 2019-09-30 | −$373.7k | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2019-01-01 to 2019-09-30 | −$1.5m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2019-07-01 to 2019-09-30 | −$0.48 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 9 months, 2019-01-01 to 2019-09-30 | −$2.13 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 9 months, 2019-01-01 to 2019-09-30 | −$332.3k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | at 2019-09-30 | $10.0k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2019-09-30 | $53.0k | us-gaap:AssetsCurrent |
| Total assets | at 2019-09-30 | $2.1m | us-gaap:Assets |
| Total liabilities | at 2019-09-30 | $1.5m | us-gaap:Liabilities |
| Shareholders' equity | at 2019-09-30 | $639.9k | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 18,568 characters.

### FORWARD LOOKING STATEMENTS

This Form 10-Q includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, included or incorporated by reference in this Form 10-Q which address activities, events or developments that the Company expects or anticipates will or may occur in the future, including such things as future capital expenditures (including the amount and nature thereof), finding suitable merger or acquisition candidates, expansion and growth of the Company’s business and operations, and other such matters are forward-looking statements. These statements are based on certain assumptions and analyses made by the Company in light of its experience and its perception of historical trends, current conditions and expected future developments as well as other factors it believes are appropriate in the circumstances.

Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve significant risks and uncertainties, and that actual results may differ materially from those projected in the forward-looking statements. Factors that could adversely affect actual results and performance include, among others, potential fluctuations in quarterly operating results and expenses, government regulation, technology change and competition. Consequently, all of the forward-looking statements made in this Form 10-Q are qualified by these cautionary statements and there can be no assurance that the actual results or developments anticipated by the Company will be realized or, even if substantially realized, that they will have the expected consequence to or effects on the Company or its business or operations. The Company assumes no obligations to update any such forward-looking statements.

### INTRODUCTION

On August 8, 2019, the Company entered into an Agreement and Plan of Merger (the “Reverse Merger Agreement”) by and among Clinigence Holdings, Inc., a Delaware corporation (“Clinigence”), iGambit, Inc., a Delaware corporation (“iGambit” or the “Company”), HealthDatix, Inc., a Delaware corporation and wholly owned subsidiary of iGambit (“Merger Sub”), and John Salerno, an individual and holder of shares of iGambit capital stock constituting a majority of the votes eligible to be cast by all of the stockholders of iGambit (the “Signing Stockholder”). The transactions contemplated by the Reverse Merger Agreement were consummated on October 29, 2019 (the “Closing”).

The Reverse Merger Agreement provided for the merger of Merger Sub with and into Clinigence, hereafter referred to as the “Acquisition.” As a result of the Acquisition, Merger Sub ceased to exist, and Clinigence became the surviving corporation and a direct wholly owned subsidiary of iGambit, and the former stockholders of Clinigence (the “Clinigence Stockholders”) have a direct equity ownership and controlling interest in iGambit. Merger Sub was renamed Clinigence Health Inc. iGambit was renamed Clinigence Holdings, Inc. Merger Sub was originally incorporated in Delaware on October 17, 2013 and had no operating activity prior to the reported transaction.

At the Closing, all of the outstanding shares of Clinigence common stock (the “Clinigence Shares”) were converted solely into the right to receive a number of shares of iGambit common stock (the “Company Shares”) such that the holders of outstanding equity of Clinigence immediately prior to the Closing own 85%, on a fully-diluted basis, of the outstanding equity of iGambit immediately following the Closing, and holders of outstanding equity of iGambit immediately prior to the Closing own 15%, on a fully-diluted basis, of the outstanding equity of iGambit. For each share of Clinigence Shares, each former Clinigence Stockholder received 0.22489093 shares of Company Shares after giving effect to the reverse stock split.

In connection with the Acquisition, the Company amended its certificate of incorporation to (i) effect a reverse stock split of the Company Shares at a ratio of 1 for 500 (the “Reverse Split Certificate of Amendment”), and (ii) change its name to Clinigence Holdings, Inc. to better align with the business of Clinigence (the “Name Change Certificate of Amendment”).

The Company is focused on the medical technology markets. Our primary focus is the expansion of our subsidiaries HealthDatix Inc. (“HealthDatix”) and our newly acquired subsidiary Clinigence Health Inc. (“Clinigence”).

HealthDatix is an end to end Software-as-a-Service solution that manages, reports, and analyzes critical data, enabling healthcare organizations to deliver positive patient outcomes. HealthDatix provides an opportunity for physicians to identify patients eligible for both “Annual Wellness Visits” (AWV) as well as “Chronic Care Management” both of which are reimbursed by Medicare.

The HealthDatix AWV solution offers a fully-hosted cloud service for healthcare providers to conduct the Medicare Annual Wellness Visit (AWV) program to their Medicare patients providing the patient with a 5-10 year Personalized Preventive Plan and physician reports that meet all Medicare audit requirements. The AWV is a program that allows a physician to identify those patients that have 2+ chronic conditions that require additional screening and management.

Additionally, the HealthDatix Chronic Care Management System (CCM), encompasses our FDA approved Electronic House Call system and Medicare covered platform, for continuous management of chronic care patients. The CCM platform can be tailored for individual care and health management of patients susceptible to chronic illness. The CCM platform is also designed to accumulate information from our BioDatix HealthBand, or any TeleMedicine or wearable device.

The HealthDatix, BioDatix Health Band, provides the ability to passively collect a wearers Heart Rate, Blood Oxygen, Blood Pressure, Sleep and Steps/Distance/Calories.

Clinigence is a healthcare information technology company providing an advanced, cloud-based platform that enables healthcare organizations to provide value-based care and population health management. The Clinigence platform aggregates clinical and claims data across multiple settings, information systems and sources to create a holistic view of each patient and provider and virtually unlimited insights into patient populations. Clinigence’s solutions help healthcare organizations improve the quality and cost effectiveness of care, enhance population health management and optimize provider networks.

***Assets.*** At September 30, 2019, we had $2,104,777 in total assets, compared to $2,618,466 at December 31, 2018. The decrease in total assets was primarily due to amortization of intangible assets from the acquisition of our HealthDatix subsidiary.

***Liabilities.*** At September 30, 2019, our total liabilities were $1,464,845 compared to $1,385,447 at December 31, 2018. Our current liabilities at September 30, 2019 consisted of accounts payable and accrued expenses of $740,465, accrued interest on notes payable of $27,165, amounts due to related parties of $128,476, deferred revenue of $600, notes payable of $495,593, and convertible notes payable of $72,546, whereas our current liabilities at December 31, 2018 consisted of accounts payable and accrued expenses of $480,270, accrued interest on notes payable of $32,265 amounts due to related parties of $145,367, deferred revenue of $9,192, notes payable of $52,500, convertible notes payable of $377,611, and derivative liability of $288,242.

***Stockholders’ Equity.*** Our Stockholders’ Equity was $639,932 at September 30, 2019 compared to Stockholders Equity of $1,233,019 at December 31, 2018. This decrease was primarily due to an increase in accumulated deficit during the nine months ended September 30, 2019.

### Three Months Ended SEPTEMBER 30, 2019 as Compared to Three Months Ended SEPTEMBER 30, 2018

***Revenues and Net Income.*** We had $7,550 of revenue from our HealthDatix subsidiary and a net loss of $373,749 during the three months ended September 30, 2019, compared to revenue of $22,582 and a net loss of $608,519 for the three months ended September 30, 2018. The decrease in revenue was due primarily to revenue generated by our HealthDatix subsidiary.

***General and Administrative Expenses.*** General and Administrative Expenses decreased to $187,295 for the three months ended September 30, 2019 from $207,793 for the three months ended September 30, 2018. For the three months ended September 30, 2019 our General and Administrative Expenses consisted of corporate administrative expenses of $23,232, legal and accounting fees of $45,621, employee benefits expenses (health and life insurance) of $2,269, payroll expenses of $98,245, exchange filing fees of $4,081 transfer agent expense of $1,398, rent expense of $2,449, and contract labor expense of $10,000. For the three months ended September 30, 2018 our General and Administrative Expenses consisted of corporate administrative expenses of $28,588, legal and accounting fees of $29,798, employee benefits expenses (health and life insurance) of $7,683, marketing expenses of $6,153, payroll expenses of $89,725, exchange filing fees of $8,897, transfer agent expense of $6,600, rent expense of $7,128, contract labor expense of $10,440, finders fees expense of $5,000, errors and omissions insurance expense of $5,281, and trade show expense of $2,500. The decreases from the three months ended September 30, 2018 to the three months ended September 30, 2019 relate primarily due to: (i) a decrease in employee benefits, (ii) a decrease in marketing expenses; and (iii) a decrease in consulting and commissions expenses. Costs associated with the operations of our HealthDatix and Clinigence subsidiaries are expected to increase going forward, as we expand the business operations of Clinigence and HealthDatix which would likely increase our corporate administrative expenses.

***Other Income (Expense).*** We reported interest expense of $9,995 for the three months ended September 30, 2019. We reported income from a change in fair value of derivative liability of $76,091, loss on extinguishment of debt of $95,464 and interest expense of $222,134 for the three months ended September 30, 2018.

### NINE Months Ended SEPTEMBER 30, 2019 as Compared to NINE Months Ended SEPTEMBER 30, 2018

***Revenues and Net Income (Loss).*** We had $19,175 of revenue from our HealthDatix subsidiary and a net loss of $1,503,511 during the nine months ended September 30, 2019, compared to $30,500 of revenue from our HealthDatix subsidiary and net income of $1,944,799, for the nine months ended September 30, 2018. The increase in revenue was due primarily to the revenue generated by our HealthDatix subsidiary.

***General and Administrative Expenses.*** General and Administrative Expenses decreased to $576,512 for the nine months ended September 30, 2019 from $752,930 for the nine months ended September 30, 2018. For the nine months ended September 30, 2019 our General and Administrative Expenses consisted of corporate administrative expenses of $106,277, legal and accounting fees of $85,862, employee benefits expenses (health and life insurance) of $8,468, payroll expenses of $304,346, filing fees expense of $5,690, rent expense of $17,712, transfer agent expense of $18,940, contract labor expense of $24,500, and consulting fees expense of $4,717. For the nine months ended September 30, 2018 our General and Administrative Expenses consisted of corporate administrative expenses of $32,359, legal and accounting fees of $74,378, employee benefits expenses (health and life insurance) of $28,591, marketing expenses of $49,769, payroll expenses of $298,155, exchange filing fees expense of $19,707, rent expense of $21,363, transfer agent expense of $24,475, contract labor expense of $34,640, consulting fees expense of $89,400, finders fees of $26,000, errors and omissions insurance expense of $5,281, marketing expense of $40,769, and trade show expense of $8,043. The decreases from the nine months ended September 30, 2019 to the nine months ended September 30, 2018 relate primarily due to: (i) a decrease in employee benefits, (ii) a decrease in marketing expenses; (iii) a decrease in filing fees expenses, and (iv) a decrease in consulting and fees expenses. Costs associated with the operations of our HealthDatix and Clinigence subsidiaries are expected to increase going forward, as we expand the business operations of Clinigence and HealthDatix which would likely increase our corporate administrative expenses.

***Other Income (Expense).*** We reported income from a change in fair value of derivative liability of $98,944, loss on extinguishment of debt of $262,566 and interest expense of $234,314 for the nine months ended September 30, 2019. We reported expense from a change in fair value of derivative liability of $(128,100), loss on extinguishment of debt of $233,734 and interest expense of $314,975 for the nine months ended September 30, 2018.

### Liquidity and Capital Resources AND ABILITY TO CONTINUE AS A GOING CONCERN

### General

As reflected in the accompanying consolidated financial statements, at September 30, 2019, we had $10,029 of cash and stockholders’ equity of $639,932. At December 31, 2018, we had $369 of cash and stockholders’ equity of $1,233,019.

Our primary capital requirements in 2019 are likely to arise from the expansion of our HealthDatix and Clinigence operations. It is not possible to quantify those costs at this point in time, in that they depend on HealthDatix’s and Clinigence’s business opportunities and the state of the overall economy. We anticipate raising capital in the private markets to cover any such costs, though there can be no guaranty we will be able to do so on terms we deem to be acceptable. We do not have any plans at this point in time to obtain a line of credit or other loan facility from a commercial bank.

While we believe in the viability of our strategy to improve HealthDatix’s and Clinigence’s sales volume, and in our ability to raise additional funds, there can be no assurances that we will be able to fully effectuate our business plan.

We believe we will continue to increase our cash position and liquidity for the foreseeable future. We believe we have enough capital to fund our present operations.

### Cash Flow Activity

Net cash used in operating activities was $332,349, for the nine months ended September 30, 2019, compared to $712,767 for the nine months ended September 30, 2018. Our primary use of operating cash flows from operating activities was from net losses of $1,503,511 and $1,944,799 for the nine months ended September 30, 2019 and 2018, respectively. Additional contributing factors to the change were from depreciation expense of $742, amortization expense of $521,902, non-cash interest expense of $231,563, stock based compensation of $1,025, loss on the extinguishment of debt of $262,566, a change in fair value of derivative liability of $98,944, decrease in accounts receivable of $4,871, a decrease in inventory of $85, an increase in prepaid expenses of $5,971, a decrease in deposits of $1,720, an increase in accounts payable and accrued expenses of $260,195, and a decrease in deferred revenue of $8,592.

There was no cash used in investing activities for the nine months ended September 30, 2019 and 2018, respectively.

Net Cash provided by financing activities was $342,009 for the nine months ended September 30, 2019 compared to $706,500 for the nine months ended September 30, 2018. The cash flows provided by financing activities for the nine months ended September 30, 2019 was primarily from $443,093 in proceeds from notes payable.

### Plan of Operation and Funding

The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has an accumulated deficit of $13,966,325, and a working capital deficit of $1,411,857 at September 30, 2019. These factors, among others, raise substantial doubt about the ability of the Company to continue as a going concern for a reasonable period of time. The Company’s continuation as a going concern is dependent upon its ability to obtain necessary equity financing and ultimately from generating revenues from its newly acquired subsidiary to continue operations. The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

We expect that working capital requirements will continue to be funded through a combination of our existing funds and further issuances of securities. Our working capital requirements are expected to increase in line with the growth of our business. Existing working capital, further advances and debt instruments, and anticipated cash flow are expected to be adequate to fund our operations over the next twelve months. We have no lines of credit or other bank financing arrangements. Generally, we have financed operations to date through the proceeds of the private placement of equity and debt instruments. In connection with our business plan, management anticipates additional increases in operating expenses and capital expenditures relating to: (i) developmental expenses associated with a start-up business and (ii) marketing expenses. We intend to finance these expenses with further issuances of securities, and debt issuances. Thereafter, we expect we will need to raise additional capital and generate revenues to meet long-term operating requirements. Additional issuances of equity or convertible debt securities will result in dilution to our current shareholders. Further, such securities might have rights, preferences or privileges senior to our common stock. Additional financing may not be available upon acceptable terms, or at all. If adequate funds are not available or are not available on acceptable terms, we may not be able to take advantage of prospective new business endeavors or opportunities, which could significantly and materially restrict our business operations.

## Controls and procedures

As filed, 1,916 characters.

### Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our chief executive officer and chief financial officer, evaluated the effectiveness of our disclosure controls and procedures pursuant to Rule 13a-15 under the Exchange Act, as of the end of the period covered by this Quarterly Report on Form 10-Q.

Based on this evaluation, our chief executive officer and chief financial officer concluded that, as of September 30, 2019, our disclosure controls and procedures are designed at a reasonable assurance level and are effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure.

### Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting that occurred during the quarter ended September 30, 2019 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

### Limitations on Effectiveness of Controls and Procedures

In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs.

Filed Nov 19, 2019.
Source: SEC EDGAR, the filing index for accession 0001607062-19-000457. Last ingested by Listed: Nov 14, 2026, 12:46 ET. No prices; not investment advice.
